EIP
VNDA icon

Epoch Investment Partners’s Vanda Pharmaceuticals VNDA Stock Holding History

Epoch Investment Partners’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-706,570
Closed -$4.8M – 463
2023
Q1 		$4.8M Sell
706,570
-690,707
-49% -$4.86M 0.03% 297
2022
Q4 		$10.3M Sell
1,397,277
-1,326,875
-49% -$12.9M 0.06% 269
2022
Q3 		$26.9M Sell
2,724,152
-33,494
-1% -$354K 0.18% 173
2022
Q2 		$30.1M Buy
2,757,646
+178,434
+7% +$1.85M 0.18% 170
2022
Q1 		$29.2M Buy
2,579,212
+617,829
+31% +$8.12M 0.14% 183
2021
Q4 		$30.8M Sell
1,961,383
-19,514
-1% -$340K 0.16% 173
2021
Q3 		$34M Buy
1,980,897
+136,207
+7% +$2.39M 0.19% 159
2021
Q2 		$39.7M Buy
1,844,690
+685,481
+59% +$12.3M 0.21% 140
2021
Q1 		$17.4M Buy
+1,159,209
New +$18.8M 0.08% 201

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Epoch Investment Partners's VNDA Position: Q2 2023 in Review

Epoch Investment Partners sold out of Vanda Pharmaceuticals (VNDA) in Q2 2023, closing a stake of 706,570 shares — an estimated $4.8M sold.

Epoch Investment Partners first reported a position in VNDA in Q1 2021 and held it in 9 quarters. The position peaked at $39.7M in Q2 2021. 188 funds tracked by Wall St. Rank hold VNDA as of Q2 2023.

  • Epoch Investment Partners reported no remaining Vanda Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Epoch Investment Partners sold 706,570 Vanda Pharmaceuticals shares in Q2 2023, an estimated $4.8M.
  • Epoch Investment Partners first reported a position in Vanda Pharmaceuticals in Q1 2021 and held it in 9 quarters.
  • Epoch Investment Partners's Vanda Pharmaceuticals position peaked at $39.7M in Q2 2021.
  • 188 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2023.

Based on Epoch Investment Partners's 13F filing for Q2 2023, filed 11 Aug 2023.